Pyxis Oncology, Inc.
PYXSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Pyxis Oncology, Inc. (PYXS) is listed under Biotechnology. Valued at $141.3M, PYXS is a micro-cap name in its sector. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Market Cap
$141.3M
Beta
1.31
P/E (TTM)
—
P/E (Fwd)
-1.85
EPS (TTM)
$-1.29
EPS (Fwd)
$-1.21
ROE
-121.7%
ROA
-51.9%
Cash
$41.0M
Total Debt
$18.3M
Free CF
-$34.5M
52W Change
97.4%
Annual Financials
Cash vs Debt
Where PYXS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, PYXS finished 21.81% above its 150-day moving average ($1.88) and 2.14% below its 200-day moving average ($2.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PYXS overbought or oversold?
At the July 15, 2026 close, PYXS's RSI(14) was 53.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $41.0M in cash comfortably exceeding the $18.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$34.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -121.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, PYXS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pyxis Oncology, Inc. and its sector.